1. 2094 Randomized controlled trial on the skin toxicity of panitumumab in third line treatment of KRAS Exon2 wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol With Panitumumab: J-STEPP): Updated analysis of anti-tumor efficacy. (September 2015) Authors: Kobayashi, Y.; Yuki, S.; Kawamoto, Y.; Sawada, K.; Miyagishima, T.; Ehira, N.; Iwanaga, I.; Okuda, H.; Tateyama, M.; Tsuji, Y.; Hatanaka, K.; Nakamura, M.; Kudo, M.; Fukushima, H.; Tagaki, T.; Hisai, H.; Koike, M.; Abe, R.; Sakata, Y.; Komatsu, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S359 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2096 Phase II trial of Irinotecan plus S-1 (IRIS) with Cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type of metastatic colorectal cancer (mCRC): HGCSG0902 updated analysis. (September 2015) Authors: Nakamura, M.; Yuki, S.; Nakatsumi, H.; Muto, O.; Hosokawa, A.; Kato, T.; Iwanaga, I.; Hatanaka, K.; Tsuji, Y.; Sato, A.; Eto, K.; Furukawa, K.; Okuda, H.; Onodera, M.; Fujikawa, K.; Kudo, M.; Yokoyama, S.; Honda, T.; Sakata, Y.; Komatsu, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC). (September 2015) Authors: Falcone, A.; Garcia-Carbonero, R.; Tabernero, J.; Sobrero, A.; Peeters, M.; Zaniboni, A.; Hochster, H.; Lenz, H.J.; Tran, B.; Yamaguchi, K.; Muro, K.; Denda, T.; Tsuji, Y.; Wahba, M.; Benedetti, F.; Ohtsu, A.; Mayer, R.J.; Van Cutsem, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2168 Predictive biomarker analysis of early tumor shrinkage induced by FOLFIRI+Bev for patients with metastatic colorectal cancer in WJOG4407G study. (September 2015) Authors: Tsuji, Y.; Yamazaki, K.; Oba, M. Saito; Sakai, K.; Nagase, M.; Ueda, S.; Tamagawa, H.; Tamura, T.; Moriwaki, T.; Murata, K.; Taira, K.; Denda, T.; Funai, S.; Tsuda, T.; Tsushima, T.; Boku, N.; Hyodo, I.; Yamanaka, T.; Tsurutani, J.; Nishio, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Issue 3 (1st May 2008) Authors: Kobayashi, H.; Yamada, Y.; Sado, T.; Sakata, M.; Yoshida, S.; Kawaguchi, R.; Kanayama, S.; Shigetomi, H.; Haruta, S.; Tsuji, Y.; Ueda, S.; Kitanaka, T. Journal: International journal of gynecological cancer Issue: Volume 18:Issue 3(2008) Page Start: 414 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0315 High disease activity at baseline, not rf nor acpa status, predicts inadequate response to methotrexate (MTX) in patients with early rheumatoid arthritis in real world: a single centrecohort in japan. (12th June 2018) Authors: Aramaki, T.; Ueki, Y.; Kojima, K.; Kurushima, S.; Tsuji, Y.; Kawachi, N.; Iwamoto, N.; Ichinose, K.; Terada, K.; Eguchi, K.; Kawakami, A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0500 Efficacy and safety of tofacitinib (TOF) in patients with rheumatoid arthritisat 52 weeks in clinical practice. (12th June 2018) Authors: Aramaki, T.; Kojima, K.; Kurushima, S.; Tsuji, Y.; Kawachi, N.; Iwamoto, N.; Ichinose, K.; Terada, K.; Eguchi, K.; Ueki, Y.; Kawakami, A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. AB1232 ORAL DYSBIOSIS REFLECTS THE IMMUNOLOGICAL ALTERATION OF RA REGARDING TO ACPA AND HLA DRB1*SE: NAGASAKI ISLAND STUDY. (2nd June 2020) Authors: Tsuji, Y.; Tamai, M.; Morimoto, S.; Sasaki, D.; Nagayoshi, M.; Nonaka, F.; Kawashiri, S. Y.; Yanagihara, K.; Saito, T.; Aoyagi, K.; Maeda, T.; Matsuda, F.; Kawakami, A. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1907 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Issue 4 (1st July 2006) Authors: Yagyu, T.; Tsuji, Y.; Haruta, S.; Kitanaka, T.; Yamada, Y.; Kawaguchi, R.; Kanayama, S.; Tanase, Y.; Kurita, N.; Kobayashi, H. Journal: International journal of gynecological cancer Issue: Volume 16:Issue 4(2006) Page Start: 1545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Advanced multi-step brazing for fabrication of a divertor heat removal component. (9th March 2021) Authors: Tokitani, M.; Hamaji, Y.; Hiraoka, Y.; Masuzaki, S.; Tamura, H.; Noto, H.; Tanaka, T.; Tsuneyoshi, T.; Tsuji, Y.; Muroga, T.; Sagara, A.; Design Group, the FFHR Journal: Nuclear fusion Issue: Volume 61:Number 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗